Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to determine benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.

This is a protocol.

Health topics:

Cancer > Haematological malignancies > Multiple myeloma

Published:

26 April 2020

Authors:

Langer P, Monsef I, Scheid C, Skoetz N

Primary Review Group:

Haematology Group

See the full Review on

the Cochrane Library

►

Print
PDF
Citation
Langer P, Monsef I, Scheid C, Skoetz N. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD013595. DOI: 10.1002/14651858.CD013595.

Don't show again

What role do you identify with the most?

General public, patient, or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.